Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Background: Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and tolerability of epirubicin (E)/cyclophosphamide (C) followed by docetaxel (Doc) with a dose-dense 5-fluorouracil (F)+E+ C regimen. Methods:...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 March 2016
|
| In: |
British journal of cancer
Year: 2016, Jahrgang: 114, Heft: 8, Pages: 863-871 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/bjc.2016.82 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1038/bjc.2016.82 Verlag, Volltext: https://www.nature.com/articles/bjc201682 
|
| Verfasserangaben: | W. Janni, N. Harbeck, B. Rack, D. Augustin, J. Jueckstock, A. Wischnik, K. Annecke, C. Scholz, J. Huober, T. Zwingers, T.W.P. Friedl and M. Kiechle |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681100401 | ||
| 003 | DE-627 | ||
| 005 | 20230426153735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191105s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bjc.2016.82 |2 doi | |
| 035 | |a (DE-627)1681100401 | ||
| 035 | |a (DE-599)KXP1681100401 | ||
| 035 | |a (OCoLC)1341250281 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Janni, Wolfgang |e VerfasserIn |0 (DE-588)135832640 |0 (DE-627)57224651X |0 (DE-576)300670370 |4 aut | |
| 245 | 1 | 0 | |a Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer |b final survival analysis of the ADEBAR study |c W. Janni, N. Harbeck, B. Rack, D. Augustin, J. Jueckstock, A. Wischnik, K. Annecke, C. Scholz, J. Huober, T. Zwingers, T.W.P. Friedl and M. Kiechle |
| 264 | 1 | |c 31 March 2016 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.11.2019 | ||
| 520 | |a Background: Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and tolerability of epirubicin (E)/cyclophosphamide (C) followed by docetaxel (Doc) with a dose-dense 5-fluorouracil (F)+E+ C regimen. Methods: The ADEBAR study was a randomised phase III trial for women with primary invasive breast cancer and ≥4 metastatic axillary lymph nodes (n=1364). Treatment consisted of four 21-day cycles of E plus C, followed by four 21-day cycles of Doc (EC-Doc), or six 28-day cycles of E plus F plus C (FEC120). Results: Disease-free survival (DFS) was similar in the two treatment arms as shown by multivariate Cox regression adjusted for other prognostic factors (EC-Doc vs FEC120, hazard ratio (HR): 1.087; 95% confidence interval (CI): 0.878-1.346, P=0.444). In addition, there was no significant difference in overall survival (OS) between the two groups (HR: 0.974; 95% CI: 0.750-1.264, P=0.841). Haematologic toxicity was more common in FEC120 recipients; non-haematologic toxicities occurred more frequently in the EC-Doc arm. The serious adverse event rate was significantly higher in the FEC120 group (29.7% vs 22.5%). Conclusions: EC-Doc provides a feasible and effective alternative therapy option to FEC120 with a different safety profile in this high-risk breast cancer cohort. | ||
| 700 | 1 | |a Wischnik, Arthur |d 1952- |e VerfasserIn |0 (DE-588)1067478655 |0 (DE-627)818787961 |0 (DE-576)426689615 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d Edinburgh : Nature Publ. Group, 1947 |g 114(2016), 8, Seite 863-871 |h Online-Ressource |w (DE-627)320420094 |w (DE-600)2002452-6 |w (DE-576)103746854 |x 1532-1827 |7 nnas |a Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer final survival analysis of the ADEBAR study |
| 773 | 1 | 8 | |g volume:114 |g year:2016 |g number:8 |g pages:863-871 |g extent:9 |a Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer final survival analysis of the ADEBAR study |
| 856 | 4 | 0 | |u https://doi.org/10.1038/bjc.2016.82 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bjc201682 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191105 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1067478655 |a Wischnik, Arthur |m 1067478655:Wischnik, Arthur |d 60000 |d 61300 |e 60000PW1067478655 |e 61300PW1067478655 |k 0/60000/ |k 1/60000/61300/ |p 6 | ||
| 999 | |a KXP-PPN1681100401 |e 3537475764 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 05.11.2019"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"31 March 2016"}],"title":[{"subtitle":"final survival analysis of the ADEBAR study","title_sort":"Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer","title":"Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer"}],"language":["eng"],"person":[{"given":"Wolfgang","role":"aut","family":"Janni","display":"Janni, Wolfgang"},{"family":"Wischnik","display":"Wischnik, Arthur","given":"Arthur","role":"aut"}],"id":{"doi":["10.1038/bjc.2016.82"],"eki":["1681100401"]},"relHost":[{"recId":"320420094","pubHistory":["Volume 1, issue 1 (1 March 1947)-"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320420094"],"issn":["1532-1827"],"zdb":["2002452-6"]},"disp":"Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer final survival analysis of the ADEBAR studyBritish journal of cancer","language":["eng"],"part":{"issue":"8","text":"114(2016), 8, Seite 863-871","pages":"863-871","year":"2016","volume":"114","extent":"9"},"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 27.10.25"],"origin":[{"publisher":"Nature Publ. Group ; Churchill Livingstone","dateIssuedKey":"1947","publisherPlace":"Edinburgh ; Edinburgh","dateIssuedDisp":"1947-"}],"titleAlt":[{"title":"BJC"}],"title":[{"title_sort":"British journal of cancer","subtitle":"BJC","title":"British journal of cancer"}]}],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["W. Janni, N. Harbeck, B. Rack, D. Augustin, J. Jueckstock, A. Wischnik, K. Annecke, C. Scholz, J. Huober, T. Zwingers, T.W.P. Friedl and M. Kiechle"]},"recId":"1681100401"} | ||
| SRT | |a JANNIWOLFGRANDOMISED3120 | ||